Akoya Biosciences Inc

Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational and clinical research. The company was founded by Garry Nolan, Yury Goltsev and Nikolay Samusik in 2015 and is headquartered in Marlborough, MA.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MARLBOROUGH, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today highlighted the industry-leading scale and speed in whole-slide, spatial biology workflows enabled by the recently launched PhenoCycler®-Fusion 2.0 and PhenoImager® HT 2.0 platform upgrades. Enhancements to the PhenoCycler-Fusion 2.0 System allow customers to process twice as many samples per week, making it the highest throughput spatial discovery platform on the market. The PhenoImager 2.0 platform delivers a 5x workflow improvement by enabling rapid real-time image analysis directly on the HT instrument. With an unprecedented ability to perform whole-slide spatial biology at scale, Akoya's customers can accelerate progress towards new discoveries, identification of clinically relevant biomarkers, and development of novel spatial signatures.

Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms

Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Priyam Shah - IR Brian McKelligon - CEO John Ek - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Lucas Baranowski - UBS Rachel Vatnsdal - JPMorgan Chase Mark Massaro - BTIG Edmund Tu - Morgan Stanley Tim Chiang - Capital One David Westenberg - Piper Sandler Mason Carrico - Stephens Inc. Operator Good day and welcome to the Akoya Biosciences Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Akoya Biosciences, Inc. (AKYA) Q2 2023 Earnings Call Transcript

Akoya Biosciences (AKYA) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.47 per share a year ago.

Akoya Biosciences (AKYA) Reports Q2 Loss, Tops Revenue Estimates

Q2 2023 revenue $23.5 million, 31% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million

Akoya Reports Record Revenue in the Second Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance

MARLBOROUGH, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences , Inc. (Nasqad: AKYA)(“Akoya), The Spatial Biology Company®, today announced a momentous achievement - publication of the 1,000th peer-reviewed article citing use of the company's technology, the largest publication volume in the industry. Approximately 80% of these articles have been published in the last 2.5 years, reflecting the exponential growth in adoption of Akoya's solutions.

Akoya Biosciences Announces Milestone of 1,000 Peer-Reviewed Publications Citing Use of its Spatial Biology Technologies

American Assets

American Vanguard

Cannae Hlds

Domo

Enviva Partners

National Vision Hlds

Globalstar

Heartland Express

I3 Verticals

MillerKnoll

PacWest Bancorp

Pebblebrook Hotel Trust

Pulse Biosciences

B. Riley Financial

Skillz

ACELYRIN Inc

SPDR S&P 500 ETF Trust

Stellar Bancorp Inc

StepStone Group

Washington Federal

Zumiez

After covering second-quarter corporate insider activity among mid-cap and large-caps, today's article will cover on the most interesting insider purchases for small-cap companies. Corporate insiders at American Assets Trust, National Vision, Skillz, Enviva, Heartland Express, and Zumiez have been buying significant amounts of shares, signaling confidence in their respective companies. Other notable insider activity among small-cap stocks includes B. Riley Financial, Cannae Holdings, i3 Verticals, whose CEOs have bought million worth of stock in the second quarter.

Strong Small-Cap Insider Buys: Q2 2023

MARLBOROUGH, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be participating in three upcoming investor conferences.

Akoya to Participate at Three Upcoming Investor Conferences

The average of price targets set by Wall Street analysts indicates a potential upside of 116.1% in Akoya (AKYA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can Akoya (AKYA) Climb 116.14% to Reach the Level Wall Street Analysts Expect?

MARLBOROUGH, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of 2023 after the market close on Monday, August 7th, 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Akoya to Report Second Quarter 2023 Financial Results on August 7th, 2023

Akoya Biosciences makes single-cell imaging solutions to aid in phenotyping cells. The company is not profitable.

Why Shares of Akoya Biosciences Jumped on Tuesday

MARLBOROUGH, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be participating in two upcoming investor conferences.

Akoya to Participate at Two Upcoming Investor Conferences

MARLBOROUGH, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the pricing of its public offering of 8,700,000 shares of common stock (the “Offering”) at a public offering price of $5.00 per share for gross proceeds of approximately $43.5 million, without giving effect to the underwriting discount and commission as well as estimated expenses payable by Akoya. Akoya has granted the underwriters a 30-day option to purchase up to an additional 1,305,000 shares of its common stock at the public offering price. The closing of the Offering is expected to occur on June 12, 2023, subject to the satisfaction of customary closing conditions.

Akoya Biosciences Announces Pricing of Public Offering of Common Stock

Shares of Akoya Biosciences AKYA, -2.46% on Wednesday dropped 10% to $5.00 in after-hours trading after the company said it fired its chief medical officer and chief people officer as part of a cost-cutting plan.

Akoya Biosciences shares fall 10% on executive exits, stock offering

MARLBOROUGH, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced it has launched an underwritten public offering of shares of its common stock (the “Offering”). In addition, Akoya expects to grant the underwriters a 30-day option to purchase additional shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Akoya Biosciences Announces Public Offering of Common Stock

Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Priyam Shah - Investor Relations Brian McKelligon - Chief Executive Officer John Ek - Chief Financial Officer Conference Call Participants Tim Chiang - Capital One Mason Carrico - Stephens Inc Ruizhi Qin - JPMorgan Vivian Bais - BTIG Kyle Mikson - Canaccord Genuity David Westenberg - Piper Sandler Lucas Baranowski - UBS Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences First Quarter 2023 Earnings Conference Call.

Akoya Biosciences, Inc. (AKYA) Q1 2023 Earnings Call Transcript

Akoya Biosciences (AKYA) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.44 per share a year ago.

Akoya Biosciences (AKYA) Reports Q1 Loss, Tops Revenue Estimates

Q1 2023 revenue $21.4 million, 27% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million

Akoya Reports Record Revenue in the First Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance

MARLBOROUGH, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced it has shipped it's 1,000th instrument, a significant milestone for the company and the largest installed base in the spatial biology industry. Akoya platforms have gained widespread adoption in discovery and translational research laboratories around the world, setting the stage for clinical use. Akoya's industry leading instrument portfolio includes the PhenoCycler®, PhenoImager® Fusion and the PhenoImager HT.

Akoya Biosciences Marks Milestone Achievement with Shipment of 1,000th Spatial Biology Instrument

MARLBOROUGH, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the launch of PhenoCode™ Discovery Panels, which simplify spatial biology workflows performed on the company's PhenoCycler-Fusion platform, at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida, April 14-19, 2023.

Akoya Biosciences Introduces PhenoCode Discovery Panels to Simplify PhenoCycler-Fusion Workflow

MARLBOROUGH, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced they are partnering with Enable Medicine to introduce a cloud platform capable of significantly accelerating the analysis of high plex spatial image datasets generated by Akoya's PhenoCycler-Fusion system. Demos of the cloud platform will be available at the Akoya booth (#1713) at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida, April 14-19, 2023.

Akoya Biosciences and Enable Medicine Introduce Cloud Platform to Power Faster Analysis of PhenoCycler-Fusion Data

MARLBOROUGH, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2023 after the market close on Monday, May 8th, 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Akoya to Report First Quarter 2023 Financial Results on May 8th, 2023

Joe Driscoll to Retire After More than Four Successful Years as Chief Financial Officer

Akoya Biosciences Announces Leadership Transition

Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q4 2022 Earnings Conference Call March 6, 2023 5:00 PM ET Company Participants Priyam Shah - Head, Investor Relations Brian McKelligon - Chief Executive Officer Joe Driscoll - Chief Financial Officer Conference Call Participants John Sourbeer - UBS Kyle Mikson - Canaccord Mason Carrico - Stephens Tejas Savant - Morgan Stanley Mark Massaro - BTIG David Westenberg - Piper Sandler Tim Chiang - Capital One Operator Thank you for standing by. And welcome to the Akoya Biosciences Fourth Quarter 2022 Earnings Conference Call.

Akoya Biosciences, Inc. (AKYA) Q4 2022 Earnings Call Transcript

Akoya (AKYA) delivered earnings and revenue surprises of -21.95% and 1.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates

Q4 2022 revenue $21.2 million and FY 2022 revenue $74.9 million FY 2023 revenue guidance range $95-98 million

News for Akoya Biosciences Inc Stock (AKYA)